NICE backs Velcade, SGLT2 diabetes meds for new uses; Novartis chief keeps faith in performance pricing;

@FiercePharma: Sun Pharma said to be in talks to buy Intas for $2.3B. FiercePharmaAsia report | Follow @FiercePharma

@EricPFierce: Bulgarian vet drug company Huvepharma picks up 3 plants from Zoetis for $40M. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: With FDA nod, Actelion adds blockbuster hopeful Uptravi to PAH portfolio. More | Follow @CarlyHFierce

> U.K. cost-effectiveness watchdogs backed Johnson & Johnson's ($JNJ) Velcade in mantle cell lymphoma, and three SGLT2 diabetes drugs--J&J's Invokana, AstraZeneca's ($AZN) Forxiga and Eli Lilly & Co. ($LLY) and Boehringer Ingelheim's Jardiance--as monotherapies in certain patients. Report

> Novartis ($NVS) CEO Joe Jimenez continues to back performance-based pricing for meds, saying that such models will have more effect on drug costs that legislation can. Report

> Sanofi ($SNY) submitted its insulin-plus-GLP-1 diabetes drug LixiLan to the FDA, hoping for an approval next year; one half of that med, the GLP-1 Lyxumia, is awaiting an FDA nod now. Release | More

Medical Device News

@FierceMedDev: ICYMI yesterday: Study: Boston Sci's Watchman more cost-effective than drugs in the long term. Article | Follow @FierceMedDev

@EmilyWFierce: ICYMI yesterday: Olympus played down early report of superbug infections linked to duodenoscope devices. Report | Follow @EmilyWFierce

@VarunSaxena2: UPDATED: Medical device tax suspended in $1.8T federal budget. Story | Follow @VarunSaxena2

> Italian orthopedic implant maker Lima trades hands from one investor to another. Story

> U.K. scientists roll out computer program for drug-resistant bacteria Dx. Report

> Theranos blows its top over WSJ reports on proprietary testing. Article

Biotech News

@FierceBiotech: Columbia U. scientists spotlight a promising proteasome approach in preventing Alzheimer's. FierceBiotechResearch article | Follow @FierceBiotech

@JohnCFierce: I don't get to mention baseball much in my work. Today I get the Mets. More from FierceBiotechResearch | Follow @JohnCFierce

@DamianFierce: hashtag infinitesimal innovation. More from Forbes | Follow @DamianFierce

> Shire's Baxalta buyout looks more and more likely as year winds down. Report

> Sanofi takes an FDA shortcut with its diabetes combo, racing with Novo. Story

> AstraZeneca bags FDA OK on gout drug lesinurad as safety doubts linger. Article

Biotech Research News

> Moneyball's analytics wiz DePodesta joins Scripps' Big Data team. News

> Transatlantic research team spotlights promise of mTOR drugs for follicular lymphoma. Report

> An intriguing anti-aging drug target may also work on PTSD. Story

> Candidate Clinton calls for $2B in annual Alzheimer's R&D support. Item

> Columbia U. scientists spotlight a promising proteasome approach in preventing Alzheimer's. Article

Vaccines News

> In $171M deal, Bavarian Nordic and J&J's Janssen extend efforts to HPV. More

> GlaxoSmithKline launched new e-commerce platform for vaccines, pharma products. Story

> Vaxart initiates PhI trial of oral influenza B vaccine. Item

> European MERS vaccine effective in camels. Report

> Sanofi's dengue vaccine gets first Asian approval with more discussions underway. Article

Pharma Marketing News

> Going beyond smiling, happy patients: Is better creative on the pharma horizon? More

> Celgene buries the hatchet with India's Natco over generic Revlimid. Item

> Price and reputation are indubitably, inexorably intertwined. Report

> Outcome-based healthcare needs outcome-based marketing. Article

> Pharma marketers steer through changing tides. Story

And Finally... Public health officials are pushing for wider use of a Gilead Sciences ($GILD) drug to prevent HIV infection, but some AIDS groups continue to oppose it. Report

Suggested Articles

A Missouri jury in 2017 ordered Johnson & Johnson to pay $110 million to plaintiff Lois Slemp, but now the verdict has been overturned.

Gilead Sciences has found a new chief financial officer in an appointment that has mergers and acquisitions written all over it.

Pfizer's role as the hero in ramping up production of a chemo drug badly needed by pediatric oncologists is a turnabout for the drugmaker.